Ingenious Targeting Laboratory

Ingenious Targeting Laboratory

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Ingenious Targeting Laboratory is a long-established, specialized service provider in the preclinical animal model space, leveraging over 25 years of experience in genetic engineering. The company operates as a contract research organization (CRO), offering custom model generation (knockout, knockin, humanized, transgenic), access to a catalog of over 10,000 models, and integrated preclinical phenotyping services. Its value proposition centers on rigorous U.S.-based quality control, expertise in complex allele design for long-term stability, and the provision of study-ready cohorts on reproducible genetic backgrounds. With a track record of 2,500+ projects and 800+ publications, ITL serves as a critical partner for researchers requiring high-fidelity animal models for target validation and translational research.

Genetics & GenomicsCRISPR

Technology Platform

Technology-agnostic integrated platform for custom genetically engineered mouse model (GEMM) creation. Utilizes appropriate genome-editing technologies (e.g., CRISPR) followed by a systematic workflow encompassing allele design, construct synthesis, embryo injection, germline transmission, and colony expansion on controlled C57BL/6 backgrounds. Emphasis on structured allele design for long-term stability and reproducibility.

Funding History

2
Total raised:$5M
Series A$5M
SeedUndisclosed

Opportunities

Growing demand for complex humanized and knock-in models to support biologics and precision medicine research.
Expansion into integrated preclinical services (phenotyping, PK/PD) creates a higher-value, full-service offering for clients.
The reproducibility crisis in research heightens the value of providers offering standardized, genetically controlled models and cohorts.

Risk Factors

Core service of custom model generation faces competition from the democratization of CRISPR technology and lower-cost offshore CROs.
Reliance on academic and pharmaceutical R&D budgets, which are subject to economic and funding cycles.
Operational biological risks inherent in complex genetic engineering projects could impact delivery timelines and reputation.

Competitive Landscape

ITL competes with other specialized animal model CROs (e.g., Taconic Biosciences, Cyagen, The Jackson Laboratory's Custom Model Services) and academic core facilities. Its differentiation is based on 25+ years of experience, a focus on complex allele design for stability, rigorous U.S.-based QC, and the provision of study-ready cohorts on pure C57BL/6 backgrounds. Competition is intensifying as gene-editing tools become more accessible.